articleClinical Pharmacology & TherapeuticsMay 21, 2008GREEN OA

Development of a Large-Scale De-Identified DNA Biobank to Enable Personalized Medicine

Vanderbilt Health · Vanderbilt University

PubMed
Indexed incrossrefpubmed

Abstract

Our objective was to develop a DNA biobank linked to phenotypic data derived from an electronic medical record (EMR) system. An "opt-out" model was implemented after significant review and revision. The plan included (i) development and maintenance of a de-identified mirror image of the EMR, namely, the "synthetic derivative" (SD) and (ii) DNA extracted from discarded blood samples and linked to the SD. Surveys of patients indicated general acceptance of the concept, with only a minority ( approximately 5%) opposing it. As a result, mechanisms to facilitate opt-out included publicity and revision of a standard "consent to treatment" form. Algorithms for sample handling and procedures for de-identification were…

Citation impact

1,025
total citations
FWCI
28.31
Percentile
100%
References
42
Citations per year

Authors

7

Topics & keywords

Keywords
  • Biobank
  • Personalized medicine
  • Clinical pharmacology
  • Publicity
  • Sample (material)
  • Medical physics
  • Medicine
  • Family medicine
No related works found for this paper.

Funding